Literature DB >> 30715349

Quantifying the health challenges in an Australian piggery using medication records for the definition of disease resilience1.

Sarita Z Y Guy1,2, Li Li2, Peter C Thomson1,2, Susanne Hermesch2.   

Abstract

Disease resilience is the ability to maintain performance and health, despite infection challenges in the environment. The evaluation of disease resilience requires measures of environment infection challenges, along with other environmental challenges. The overall objective of this study was to define disease resilience using pedigree, production, and medication records from an Australian herd of Large White pigs. The extent to which the infection challenges were captured by environmental descriptors based on contemporary group (CG) estimates of growth was assessed (n = 8,835). There were moderately negative linear relationships (r = -0.29, p = 0.08) between CG estimates (39 CGs) of growth and the frequency of medicated pigs (n = 812 medicated pigs). This suggests that CG estimates of growth partly capture health challenges. However, because the health challenges were not of the pathogenic nature for this herd, these environmental descriptors may not be appropriate for the evaluation of disease resilience. Subsequently, an alternative approach to select for health was provided, where health was defined as a binary outcome of medication status, fitted in a generalized linear mixed sire model. Two health-trait definitions were explored, which differed in the number of control (nonmedicated) pigs per litter. The 'reduced-control' health trait had a representative sample of littermates with available performance records, and the 'full-control' health trait included all piglets weaned per litter (i.e., performance-tested and non-performance-tested pigs). All 812 medicated pigs had performance records available. The remaining 8,023 pigs in the reduced-control and 21,352 pigs in the full-control health traits were assumed to have not been medicated (controls). Male pigs from litters with a higher number of postweaning deaths were more likely to be medicated for both health traits. Heritability was consistent for both trait definitions, at 0.06 ± 0.04 (± SE) (reduced-control) and 0.04 ± 0.03 (full-control). While results may be specific for individual herds depending on health status, these estimates align with those presented in literature for other health traits. Together, these results demonstrate that routinely collected medication records may be useful for pig breeding programs and their economic importance and genetic background should be explored further.
© The Author(s) 2019. Published by Oxford University Press on behalf of the American Society of Animal Science. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  environmental descriptor; genotype by environment interaction; health; time series

Mesh:

Year:  2019        PMID: 30715349      PMCID: PMC6396246          DOI: 10.1093/jas/skz025

Source DB:  PubMed          Journal:  J Anim Sci        ISSN: 0021-8812            Impact factor:   3.159


  21 in total

1.  High physiological demands in intensively raised pigs: impact on health and welfare.

Authors:  A Prunier; M Heinonen; H Quesnel
Journal:  Animal       Date:  2010-06       Impact factor: 3.240

2.  Optimization of dairy cattle breeding programs for different environments with genotype by environment interaction.

Authors:  H A Mulder; R F Veerkamp; B J Ducro; J A M van Arendonk; P Bijma
Journal:  J Dairy Sci       Date:  2006-05       Impact factor: 4.034

3.  Meta-analysis of feed intake and growth responses of growing pigs after a sanitary challenge.

Authors:  H Pastorelli; J van Milgen; P Lovatto; L Montagne
Journal:  Animal       Date:  2012-06       Impact factor: 3.240

4.  Genetic parameters of growth in dairy cattle and associations between growth and health traits.

Authors:  S Brotherstone; M P Coffey; G Banos
Journal:  J Dairy Sci       Date:  2007-01       Impact factor: 4.034

5.  Disease incidence in dairy herds in the southern highlands district of New South Wales, Australia.

Authors:  M A Stevenson
Journal:  Prev Vet Med       Date:  2000-01-05       Impact factor: 2.670

6.  Antimicrobial use in the Australian pig industry: results of a national survey.

Authors:  D Jordan; J J-C Chin; V A Fahy; M D Barton; M G Smith; D J Trott
Journal:  Aust Vet J       Date:  2009-06       Impact factor: 1.281

7.  Traits associated with innate and adaptive immunity in pigs: heritability and associations with performance under different health status conditions.

Authors:  Mary Clapperton; Abigail B Diack; Oswald Matika; Elizabeth J Glass; Christy D Gladney; Martha A Mellencamp; Annabelle Hoste; Stephen C Bishop
Journal:  Genet Sel Evol       Date:  2009-12-30       Impact factor: 4.297

8.  Genetic parameters for performance traits in commercial sows estimated before and after an outbreak of porcine reproductive and respiratory syndrome.

Authors:  C R G Lewis; M Torremorell; L Galina-Pantoja; S C Bishop
Journal:  J Anim Sci       Date:  2008-10-24       Impact factor: 3.159

9.  A consideration of resistance and tolerance for ruminant nematode infections.

Authors:  Stephen C Bishop
Journal:  Front Genet       Date:  2012-12-14       Impact factor: 4.599

10.  Selection of pigs for improved coping with health and environmental challenges: breeding for resistance or tolerance?

Authors:  Sarita Z Y Guy; Peter C Thomson; Susanne Hermesch
Journal:  Front Genet       Date:  2012-12-14       Impact factor: 4.599

View more
  2 in total

1.  Genetic analysis of disease resilience of wean-to-finish pigs under a natural disease challenge model using reaction norms.

Authors:  Jian Cheng; KyuSang Lim; Austin M Putz; Anna Wolc; John C S Harding; Michael K Dyck; Frederic Fortin; Graham S Plastow; Jack C M Dekkers
Journal:  Genet Sel Evol       Date:  2022-02-08       Impact factor: 4.297

Review 2.  Why breed disease-resilient livestock, and how?

Authors:  Pieter W Knap; Andrea Doeschl-Wilson
Journal:  Genet Sel Evol       Date:  2020-10-14       Impact factor: 4.297

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.